The Board of Nestle India at its meeting held on 25 April 2024 has approved the launch of Nespresso in India wherein the Company will engage in the sale and distribution of Nespresso products (machines and capsules) through its distribution network, online channels, and boutiques under commercial arrangements with Nespresso and third parties. The Company expects to launch Nespresso in India by the end of 2024. Powered by Capital Market - Live News

Net profit of Nestle India rose 26.82% to Rs 934.17 crore in the quarter ended March 2024 as against Rs 736.64 crore during the previous quarter ended March 2023. Sales rose 9.28% to Rs 5254.43 crore in the quarter ended March 2024 as against Rs 4808.40 crore during the previous quarter ended March 2023.For the full year,net profit rose 64.52% to Rs 3932.84 crore in the year ended March 2024 as against Rs 2390.52 crore during the previous year ended December 2022. Sales rose 44.59% to Rs 24275.48 crore in the year ended March 2024 as against Rs 16789.53 crore during the previous year ended December 2022. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Dec. 2022% Var. Sales5254.434808.40 9 24275.4816789.53 45 OPM %25.6722.78 -23.9722.11 - PBDT1349.371092.16 24 5822.283658.98 59 PBT1240.50990.46 25 5284.503255.97 62 NP934.17736.64 27 3932.842390.52 65 Powered by Capital Market - Live News

Nestle India announced that the 65th Annual General Meeting (AGM) of the company will be held on 5 July 2024.Powered by Capital Market - Live News

Nestl� India and Dr. Reddy`s Laboratories announced that they have entered into a definitive agreement to form a joint venture to bring innovative nutraceutical brands to consumers in India and other agreed territories. The partnership will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestl� Health Science (NHSc) with the strong and established commercial strengths of Dr. Reddy`s in India. The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios in categories such as metabolic, hospital nutrition, general wellness , women`s health and child nutrition for consumers across India. The JV Company will be headquartered in Hyderabad. The JV Company will leverage the capabilities as well as services of the Nestl� Group and Dr. Reddy`s. Select brands will be licensed by the JV Partners to the JV company. The Nestl� Group will license brands such as Nature`s Bounty, Osteo Bi-Flex, Ester-C, Resource High Protein, Optifast, Resource Diabetic, Peptamen, Resource Renal and Resource Dialysis. Dr. Reddy`s will license brands such as Rebalanz, Celevida, Antoxid, Kidrich-D3, Becozinc in the nutrition, and OTC segments. The JV Company is expected to become operational in Q2 of FY`25. Powered by Capital Market - Live News

Nestle India announced that the Board of Directors of the Company at its meeting held on 25 April 2024, has recommended a Final dividend of Rs.8.50 per share (i.e.850%), subject to the approval of the shareholders.Powered by Capital Market - Live News